Mankind Pharma Limited (BOM:543904)
India · Delayed Price · Currency is INR 2,485.20
+5.25 (0.21%)
At close: Oct 6, 2026
Mankind Pharma Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 1,032,490 | 828,051 | 1,000,400 | 921,654 | - | - | |
Market Cap Growth | 2.18% | -17.23% | 8.54% | - | - | - |
Enterprise Value | 1,076,136 | 879,179 | 960,198 | 902,241 | - | - |
Last Close Price | 2494.85 | 2005.85 | 2422.20 | 2296.45 | - | - |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 50.55 | 43.29 | 50.25 | 48.18 | - | - |
PS Ratio | 7.01 | 5.80 | 8.20 | 8.98 | - | - |
PB Ratio | 6.23 | 5.00 | 6.87 | 9.63 | - | - |
P/TBV Ratio | 619.74 | 497.03 | - | 12.00 | - | - |
P/FCF Ratio | 41.38 | 33.18 | 51.24 | 50.17 | - | - |
P/OCF Ratio | 33.08 | 26.53 | 41.45 | 42.82 | - | - |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 7.30 | 6.16 | 7.87 | 8.79 | - | - |
EV/EBITDA Ratio | 27.38 | 24.22 | 31.07 | 35.87 | - | - |
EV/EBIT Ratio | 35.47 | 31.19 | 38.28 | 41.96 | - | - |
EV/FCF Ratio | 43.13 | 35.23 | 49.18 | 49.11 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.38 | 0.38 | 0.58 | 0.02 | 0.02 | 0.14 |
Debt / EBITDA Ratio | 1.61 | 1.73 | 2.74 | 0.08 | 0.09 | 0.44 |
Debt / FCF Ratio | - | 2.53 | 4.36 | 0.11 | 0.17 | 1.94 |
Net Debt / Equity Ratio | 0.25 | 0.25 | 0.41 | -0.33 | -0.18 | -0.06 |
Net Debt / EBITDA Ratio | 1.06 | 1.13 | 1.95 | -1.26 | -0.71 | -0.20 |
Net Debt / FCF Ratio | - | 1.65 | 3.08 | -1.73 | -1.32 | -0.87 |
Asset Turnover | - | 0.51 | 0.62 | 0.95 | 0.93 | 1.00 |
Inventory Turnover | - | 2.01 | 2.01 | 2.17 | 1.84 | 1.69 |
Quick Ratio | - | 0.61 | 0.72 | 2.02 | 1.14 | 0.65 |
Current Ratio | - | 1.07 | 1.23 | 3.10 | 2.32 | 1.68 |
Return on Equity (ROE) | - | 12.45% | 16.62% | 22.57% | 18.79% | 25.99% |
Return on Assets (ROA) | - | 6.31% | 7.89% | 12.40% | 10.53% | 14.76% |
Return on Invested Capital (ROIC) | 11.80% | 11.36% | 14.83% | 27.47% | 20.42% | 29.77% |
Return on Capital Employed (ROCE) | - | 13.10% | 11.40% | 21.80% | 20.20% | 28.10% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 1.98% | 2.31% | 1.99% | 2.08% | - | - |
FCF Yield | 2.42% | 3.01% | 1.95% | 1.99% | - | - |
Payout Ratio | - | 2.16% | - | - | - | - |
Buyback Yield / Dilution | -1.36% | -2.13% | -0.88% | -0.14% | -0.00% | - |
Total Shareholder Return | -1.36% | -2.13% | -0.88% | -0.14% | -0.00% | - |